10.11.2015 – 07:10

LifeWatch AG

EQS-Adhoc: LifeWatch AG: Acquisition of FlexLife Health Inc., an INR monitoring company co-founded by the Cleveland Clinic

EQS Group-Ad-hoc: LifeWatch AG / Key word(s): Acquisition
LifeWatch AG: Acquisition of FlexLife Health Inc., an INR monitoring company
co-founded by the Cleveland Clinic

10.11.2015 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
LifeWatch(R) acquires FlexLife Health Inc., an INR monitoring company co-founded
by the Cleveland Clinic

Zug/Switzerland, November 10, 2015 - LifeWatch(R) AG (SIX Swiss Exchange: LIFE),
a leading developer and provider of medical solutions and remote diagnostic
monitoring services in the digital health market, is pleased to announce the
acquisition of FlexLife Health Inc., a company offering remote patient
monitoring services in the area of coagulation measurement, by its subsidiary,
LifeWatch Services Inc.

FlexLife was founded in 2012 by the Cleveland Clinic Foundation and ZIN
Technologies, Inc. (a NASA partner for health in space) to offer home monitoring
solutions for INR (blood clotting) measurement. FlexLife offers INR monitoring
services via a proprietary web-based digital health platform that is superior to
all other current service offerings in the market. Monitoring of the INR is
essential for patients taking drugs like Warfarin (an oral anticoagulant), which
pose a risk of bleeding or clotting if dosing is not properly monitored.

LifeWatch's electrophysiologist and cardiologist relationship base have already
expressed a deep interest in remote monitoring of INR for their patients, since
the main cause of a clinical arrhythmia, detected by LifeWatch's existing
cardiac devices, is atrial fibrillation for which Warfarin is a common treatment
option. Dr. Stephan Rietiker, CEO of LifeWatch, stated: "I am excited about this
acquisition, particularly since Warfarin and similar generic anti-coagulants are
the most commonly prescribed ant-coagulant medications in the U.S. The FlexLife
product complements well our existing cardiac monitoring business and will allow
us to provide doctors and their patients needing INR therapy due to atrial
arrhythmias with a unique and easy-to-use product that will improve patient
quality of life."

LifeWatch will integrate this business into its existing operations to benefit
from synergy effects (reimbursement, distribution, etc.) and profitably grow the
business over the next few years. LifeWatch expects to commence activities
already in December this year with a full launch in the U.S. at the beginning of
2016. The parties have agreed to keep the terms of the transaction confidential.

 

For further questions:

LifeWatch AG
c/o Dynamics Group, Philippe Blangey / Doris Rudischhauser
Phone: +41 43 268 32 35 / +41 79 410 81 88
E-mail:  investor-relations@lifewatch.com

About LifeWatch AG:
LifeWatch AG, headquartered in Zug and listed on SIX Swiss Exchange (LIFE),
Switzerland, is a leading healthcare technology and solution company,
specializing in advanced digital health systems and wireless remote diagnostic
patient monitoring services. LifeWatch's services provide physicians with
critical information to determine appropriate treatment and thereby improve
patient outcomes. LifeWatch AG has operative subsidiaries in the United States,
in Switzerland and in Israel, and is the parent company of LifeWatch Services
Inc., and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a leading
U.S.-based provider of cardiac monitoring services and home sleep testing of
Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is
a leading developer and manufacturer of telemedicine products. For additional
information, please visitwww.lifewatch.com.

Sign upfor customized e-mail alerts and documentation requests at
http://www.irlifewatch.com/alert-service.aspx

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position, the
business strategy, and plans and objectives for future operations, are
forward-looking statements. The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect" and similar expressions are
intended to identify forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and projections about
future events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short-term and long-term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only on
data available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL
CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN
OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE
UNITED STATES, OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF
LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER
THE UNITED STATES
SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED
STATES OR TO U.S. PERSONS ABSENT FROM REGISTRATION UNDER OR AN APPLICABLE
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES
LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS
SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE
ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.

End of ad hoc announcement

+++++
Additional features:

Document:http://n.equitystory.com/c/fncls.ssp?u=YVJXEVSDAP
Document title: LifeWatch(R) acquires FlexLife Health Inc., an INR monitor-ing
company co-founded by the Cleveland Clinic

--------------------------------------------------------------------------------
10.11.2015 News transmitted by EQS Schweiz AG. www.eqs.com - news archive:
http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.
--------------------------------------------------------------------------------

Language: English

Company:  LifeWatch AG

          Baarerstrasse 139

          6300  Zug

          Switzerland

Phone:    +41 41 728 67 78

Internet: www.lifewatch.com

ISIN:     CH0012815459

Valor:    811189

Listed:   Regulated Unofficial Market in Berlin, Stuttgart; Open Market in
Frankfurt ; SIX


End of News EQS Group News Service

--------------------------------------------------------------------------------

410675  10.11.2015